U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06875245) titled 'Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals' on Oct. 30, 2023.
Brief Summary: This is a prospective, randomized study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomized into two groups and followed for 44 to 56 weeks.
Patients in the first group will receive 4 injections of faricimab every 4 weeks, with the next visit and injection after 8 weeks, followed by a treat-and-extend regimen with a minimal interval of 8 we...